Drugs / BAT8006
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05378737 | Jul 2022 → Dec 2025 | cancer | Bio-Thera Solutions | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT06545617 Comparator | Jan 2025 → Mar 2026 | fallopian tube cancer, primary peritoneal carcinoma | Bio-Thera Solutions | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT8006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06545617 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized monoclonal antibody” NCT05378737 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT05378737 ↗ |